Reckitt Benckiser falls after losing drug exclusivity - UPDATE

Shares in Reckitt Benckiser were hammered on Monday by the news that it has lost exclusivity over its SUBOXONE tablets after the Food and Drug Administration (FDA) gave two drug manufacturers the green light to produce generic versions of the drug.

Shares in Reckitt Benckiser were hammered on Monday by the news that it has lost exclusivity over its SUBOXONE tablets after the Food and Drug Administration (FDA) gave two drug manufacturers the green light to produce generic versions of the drug.

The RB Pharmaceuticals business (RBP) had filed a 'Citizen's Petition' to the FDA to raise the barrier to generic versions of the product, which is used in the treatment for the chronic diseases of addiction.

RBP had called for more stringent packaging standards and increased educational interventions to help lower the number of children exposed to products that contain buprenorphine - found in RBP's SUBOXONE tablets - which is used to treat opioid dependence.

Reckitt announced on Monday morning that the FDA had denied its petition, saying that existing labelling and safety programmes were "sufficient". As such, the regulator approved two generic versions of the tablet in the US, which accounted for around 5.0% of group profits last year, according to analyst Martin Deboo from Investec.

Meanwhile, analysts at Jefferies estimate that these generics "could enter the market within a month". They said that this would cut around 3.0% off full-year earnings at Reckitt and around 8.0% shed from 2014 earnings.

The broker said: "Whilst the possibility of generic entry has been a well-flagged risk for the Reckitt investment case for some time, we believe that the market had become somewhat complacent of the risks, and indeed that a number of investors had gradually come around to the view that generics would never enter the market.

"On this basis, we would expect the shares to tick down as the market gradually digests the impact of this news over the coming days."

Shares were down 3.01% at 4,380p before the close of trade in London.

Reckitt disappointedThe company said that it is "disappointed" with the decision but will continue to work with the FDA on safety enhancements.

"RBP remains committed to maintaining its own high level standards for safety, including the use of child resistant, unit-dose packaging for its buprenorphine-based opioid dependence treatment products.

"It will therefore carry on with the decision to discontinue the sale of its loose tablet bottles of SUBOXONE in the United States in favour of other effective treatment options that have shown reduced paediatric exposure rates."

Reckitt makes a wide range of household cleaning products such as Cillit Bang and Calgon, but is also responsible for brands such as Nurofen and Strepsils.

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020

Most Popular

Bitcoin: fool’s gold or the new gold?
Bitcoin

Bitcoin: fool’s gold or the new gold?

With bitcoin hitting new highs last week, and close to becoming a mainstream investment, is it really gold for the 21st century?
15 Jan 2021
The MoneyWeek Podcast: bitcoin special
Bitcoin

The MoneyWeek Podcast: bitcoin special

Merryn talks to bitcoin experts Dominic Frisby and Charlie Morris to get the lowdown on the cryptocurrency to find out why it's such a huge global phe…
15 Jan 2021
Leasehold reforms promise the end of a nightmare for many homeowners
Property

Leasehold reforms promise the end of a nightmare for many homeowners

Horror stories about unscrupulous landlords profiting from a legal relic of the feudal era are about to get a happy ending, says Simon Wilson.
16 Jan 2021